skip to main content

Explore Research Products in the NSF-PAR

  • Home
  • Search Results
  • Page 1 of 1

Search for: All records

Creators/Authors contains: "Mignon, L."

Note: When clicking on a Digital Object Identifier (DOI) number, you will be taken to an external site maintained by the publisher. Some full text articles may not yet be available without a charge during the embargo (administrative interval).
What is a DOI Number?

Some links on this page may take you to non-federal websites. Their policies may differ from this site.

  1. ; ; ; ; ; ; ; ; ; ; et al ( , Astronomy & Astrophysics)
    null (Ed.)
    We report the detection of a transiting super-Earth-sized planet ( R = 1.39 ± 0.09 R ⊕ ) in a 1.4-day orbit around L 168-9 (TOI-134), a bright M1V dwarf ( V = 11, K = 7.1) located at 25.15 ± 0.02 pc. The host star was observed in the first sector of the Transiting Exoplanet Survey Satellite (TESS) mission. For confirmation and planet mass measurement purposes, this was followed up with ground-based photometry, seeing-limited and high-resolution imaging, and precise radial velocity (PRV) observations using the HARPS and Magellan /PFS spectrographs. By combining the TESS data and PRV observations, we find the mass of L 168-9 b to be 4.60 ± 0.56 M ⊕ and thus the bulk density to be 1.74 −0.33 +0.44 times higher than that of the Earth. The orbital eccentricity is smaller than 0.21 (95% confidence). This planet is a level one candidate for the TESS mission’s scientific objective of measuring the masses of 50 small planets, and it is one of the most observationally accessible terrestrial planets for future atmospheric characterization. 
    more » « less
    Full Text Available 
  2. ; ; ; ; ; ; ; ( , Pediatric Blood & Cancer)
    Abstract Background

    Despite the intensity of hematopoietic stem cell transplantation (HCT), relapse remains the most common cause of death in juvenile myelomonocytic leukemia (JMML). In contrast to other leukemias where therapy is used to reduce leukemic burden prior to transplant, many patients with JMML proceed directly to HCT with active disease. The objective of this study was to elucidate whether pre‐HCT therapy has an effect on the molecular burden of disease and how this affects outcome post‐HCT.

     Procedure

    Twenty‐one patients with JMML who received pre‐HCT therapy and were transplanted at UCSF were analyzed in this study. The mutant allele frequency of the driver mutation was assessed before and after pre‐HCT therapy, using custom amplicon next‐generation sequencing.

     Results

    Of the 21 patients, seven patients (33%) responded to therapy with a significant reduction in their mutant allele frequency and were classified as molecular responders. Six of these patients received moderate‐intensity chemotherapy, one patient received only azacitidine. The 5‐year progression‐free survival after HCT of molecular responders was 100% versus 61% for nonresponders (P = .12). Survival of molecular nonresponders was not improved by use of high‐intensity conditioning, but patients were salvaged if they experienced severe graft versus host disease. There were no baseline clinical characteristics that were associated with response to pre‐HCT therapy.

     Conclusions

    Despite the myelodysplastic nature of JMML, patients treated with pre‐HCT therapy can achieve molecular remissions. These patients experienced a trend toward improved outcomes post‐HCT. Importantly, molecular testing can be helpful to distinguish between responders and nonresponders and should become an integral part of clinical care.

     
    more » « less